Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.: Efficacy Of DCA Treatment In SM22-5-HTT+ Mice

Archive ouverte

Guignabert, Christophe | Tu, Ly | Izikki, Mohamed | Dewachter, Laurence | Zadigue, Patricia | Humbert, Marc | Adnot, Serge | Fadel, Elie | Eddahibi, Saadia

Edité par CCSD ; Federation of American Society of Experimental Biology -

13 pages; The authors thank Michel Hamon for helpful discussions.. International audience. Voltage-gated potassium (Kv)1.5 is decreased in pulmonary arteries (PAs) of patients with idiopathic pulmonary arterial hypertension (IPAH) and in experimental models including mice with SM22alpha-targeted overexpression of the serotonin transporter (5-HTT). The mechanisms underlying these abnormalities, however, remain unknown. Dichloroacetate (DCA) inhibits chronic hypoxia- or monocrotaline-induced PAH by inhibiting nuclear factor of activated T-cells (NFAT)c2 and increasing Kv1.5. Therefore, we hypothesized that DCA could regress established PAH in SM22-5-HTT+ mice. We evaluated pulmonary hemodynamics, vascular remodeling, NFATc2, and Kv1.5 protein in 20-wk-old SM22-5-HTT+ or wild-type mice treated for 1, 7, and 21 d with DCA, cyclosporine-A (NFAT inhibitor), or vehicle. DCA partially reversed PAH in SM22-5-HTT+ mice by decreasing proliferation and increasing apoptosis in muscularized PAs. Furthermore, serotonin (10(-8)-10(-6) M) dose-dependently increased PA-smooth muscle cell (PA-SMC) proliferation in culture (EC(50)=0.97 x 10(-7) M) and DCA (5 x 10(-4) M) vs. PBS markedly reduced the growth of PA-SMC from IPAH and control patients treated with the highest dose of serotonin by 50 and 30%, respectively. Finally, although serotonin induces NFATc2 activation in PA-SMCs, inhibition of NFATc2 alone with cyclosporine-A was not sufficient for reversing PAH in this model. Our results support the possibility that DCA may be an interesting agent for investigation in patients with PAH.

Suggestions

Du même auteur

Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.: FGF2 Inhibition in Pulmonary Hypertension

Archive ouverte | Izikki, Mohamed | CCSD

12 pages. International audience. Pulmonary hypertension (PH) is a progressive, lethal lung disease characterized by pulmonary artery SMC (PA-SMC) hyperplasia leading to right-sided heart failure. Molecular events o...

Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension.

Archive ouverte | Dewachter, Laurence | CCSD

International audience. Mutations in the gene encoding bone morphogenetic protein (BMP) receptor type 2 (BMPR-2) have been reported in pulmonary arterial hypertension (PAH), but their functional relevance remains in...

Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension.. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension.: Autocrine Loop of EC-Derived FGF2 in IPAH

Archive ouverte | Tu, Ly | CCSD

International audience. Pulmonary vascular remodeling is key to the pathogenesis of idiopathic pulmonary arterial hypertension (IPAH). We recently reported that fibroblast growth factor (FGF)2 is markedly overproduc...

Chargement des enrichissements...